Stock market Updates | Astrazeneca Pharma India Ltd. | R Wadiwala Securities Pvt Ltd
investments Associate Login Online Trading Login

We are investment service provider for Buy stocks , Low Stocks Brokerage , Stocks Portfolio Management in Surat , NRI Investment in Stocks , Share Broking Surat , Stock Broking Surat , Advisory Services Surat and Competetive Stocks Brokerage. investment advisory, financial integrity and prompt services in the whole of South Gujarat.

equity
Home Markets & NewsCompany ProfileSmart Quotes

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE7173.30236.15 (+3.4 %)
PREV CLOSE (Rs.) 6937.15
OPEN PRICE (Rs.) 6941.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4822
TODAY'S LOW / HIGH (Rs.)6941.10 7377.95
52 WK LOW / HIGH (Rs.)3730 7550
NSE7172.60232.95 (+3.36 %)
PREV CLOSE( Rs. ) 6939.65
OPEN PRICE (Rs.) 6997.95
BID PRICE (QTY) 7172.60 (4)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 65755
TODAY'S LOW / HIGH(Rs.) 6946.95 7388.60
52 WK LOW / HIGH (Rs.)3750 7572.2

Smart Quotes

BSE NSE
1D 1M 3M 1Y 3Y 5Y
Stock Summary
Trade Value (Rs. in Lacs)
347.21
Dividend Yield(%)
0.33
TTM EPS (Rs.)
64.60
P/E Ratio
111.03
Book Value (Rs.)
283.45
Face Value (Rs.)
2
MCap (Rs. in Mn)
179332.50
Price/Earning (TTM)
101.63
Price/Sales (TTM)
13.84
Price/Book (MRQ)
25.31
PAT Margin (%)
12.40
ROCE (%)
33.94
company info
Incorporation Year : 11-07 1979

Management Info :

Narayan K Seshadri - Chairman Sanjeev Kumar Panchal - Managing Director

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone : 080 6774 8000

Registrars Details :

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE
News
16Jul Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that it enclosed Notice of the 45t..
03Jul Astrazeneca Pharma India informs about
Astrazeneca Pharma India has informed that the current Site Lead India O..
21Jun AstraZeneca Pharma India informs about
With reference to earlier communication dated November 16, 2023, AstraZe..
more
Financials
QTR Mar 24 ANNUAL 24
Net Profit394.7799999999991615.09
Gross Profit 543.539999999999 2195.37
Operating Profit 581.179999999999 2192.52
Net Sales 3831.99 12955.28
more
Rs. in Millions
Rolling Forward P/E (EOD)
Event Calendar
peer group
Abbott India (BSE)
Rwadiwala-peer-arrow  28637.90 (2.27%)
M.Cap (Rs. in Cr)60853.54
Divi's Lab (BSE)
Rwadiwala-peer-arrow  4792.15 (5.33%)
M.Cap (Rs. in Cr)127216.53
Alkem Laboratories (BSE)
Rwadiwala-peer-arrow  5295.80 (2.26%)
M.Cap (Rs. in Cr)63319.23
Hester Biosciences (BSE)
Rwadiwala-peer-arrow  3206.45 (3.67%)
M.Cap (Rs. in Cr)2727.68
Shareholding Pattern
PROMOTERS
75%
MUTUAL FUNDS/UTI
4.97%
NON-INSTITUTION
17.21%
FI/BANKS/INSURANCE
0%
GOVERNMENT
0%
FII
0%
more
Mf Holdings
ATTENTION INVESTORS|KYC|IPO|PROPRIETARY TRADING
Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors.    
ATTENTION INVESTORS Advisory for Investors Advisory - KYC Compliance
  • 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
  • 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • 3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors
CORPORATE OFFICE
address
  • 9/2003-4,
  • Vishnu Priya Limda Chowk
  • Main Road
  • Surat – 395 003.
fax us @ +91-261-6673537
email us @ info@rwadiwala.com

Feed Back  | Terms & Conditions  | SEBI  | FMC  | NSE  | BSE  |  Advisory For Investors  |  MCX  | IRDA  |  AMFI  | Disclaimer  | Privacy Policy  | Careers | User Agreements  | Ethics Policy  | Investor Protection  |  Dos and Don'ts   |  Rights and Obligations   |  Uniform Risk Disclosure   |   Important Policies   |  Investor Charter   |  Investor Complaints   | To File A Complaint on SCORES   |   Online Dispute Resolution Portal (ODR Portal) |   CLIENT BANK ACCOUNT DETAILS  |   Client-wise Collateral |  Complaint filing Procedure |   SOP of Centralized Mechanism for reporting the demise of an investor through KRAs |  Sitemap 

BSE, NSE, MCX SEBI Regn no.: INZ000187332 | PMS SEBI Regn no.: INP000004045 | CDSL SEBI Regn No.: IN-DP-112-2015 | CDSL DP ID: 12043100
| R Wadiwala Securities Pvt Ltd - CIN: U67120GJ2004PTC044324

Compliance Officer - Email ID: compliance@rwadiwala.com | Contact No.: 0261-6673542

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by us, our employees, and our servants.

Investor Greivance Redressal at support@rwadiwala.com

Copyright © 2016 | All Rights Reserved. R.Wadiwala group.

Designed & Developed by ●●● Accord Fintech Pvt. Ltd.